Background The monoclonal antibody ublituximab enhances antibody-dependent cellular
cytolysis and produces B-cell depletion. Ublituximab is being evaluated for the treatment of …

Background: Ublituximab, a novel monoclonal antibody (mAb) targeting a unique epitope on
the CD20 antigen, is glycoengineered for enhanced B-cell targeting through antibody …

Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …

Background Bruton's tyrosine kinase (BTK) regulates the functions of B cells and myeloid
cells that are implicated in the pathogenesis of multiple sclerosis. Evobrutinib is a selective …

Background There is increasing evidence that B lymphocytes are involved in the
pathogenesis of multiple sclerosis, and they may be a therapeutic target. Rituximab, a …

Background Multiple sclerosis (MS) is an autoimmune, demyelinating disease of the central
nervous system. The treatment of MS has always been a focus of neurological research. To …

Background B lymphocytes are implicated in the pathogenesis of multiple sclerosis. We
aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 …

We evaluated the safety, tolerability, pharmacodynamics, and activity of B‐cell depletion with
rituximab in patients with relapsing‐remitting multiple sclerosis, receiving two courses of …

Objective: B cells and the humoral immune system have been implicated in the
pathogenesis of multiple sclerosis (MS). This study sought to evaluate the efficacy, safety …

Objective To assess the onset of ocrelizumab efficacy on brain MRI measures of disease
activity in the phase II study in relapsing-remitting multiple sclerosis (RRMS), and relapse …